Icon (NASDAQ:ICLR) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, May 1st. Analysts expect Icon to post earnings of $1.62 per share for the quarter. Icon has set its FY19 guidance at $6.69-6.89 EPS.
Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 20th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.60 by $0.02. The company had revenue of $679.03 million for the quarter, compared to analysts’ expectations of $675.04 million. Icon had a net margin of 12.43% and a return on equity of 26.01%. Icon’s revenue was up 49.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.43 EPS. On average, analysts expect Icon to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.
Shares of Icon stock opened at $137.39 on Monday. The stock has a market capitalization of $7.42 billion, a P/E ratio of 21.84, a PEG ratio of 1.72 and a beta of 0.65. Icon has a 1 year low of $116.68 and a 1 year high of $155.33. The company has a current ratio of 2.18, a quick ratio of 2.18 and a debt-to-equity ratio of 0.26.
A number of equities analysts recently issued reports on the stock. Barclays upped their price target on shares of Icon from $130.00 to $140.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 21st. SunTrust Banks reiterated a “buy” rating and issued a $161.00 price target on shares of Icon in a research note on Monday, February 25th. BidaskClub cut shares of Icon from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. Wolfe Research assumed coverage on shares of Icon in a research note on Tuesday, April 2nd. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded shares of Icon from a “hold” rating to a “buy” rating and set a $146.00 price target on the stock in a research note on Wednesday, April 24th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $152.30.
WARNING: This article was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2019/04/29/icon-iclr-set-to-announce-earnings-on-wednesday.html.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Article: Understanding Market Liquidity
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.